ABSTRACT. In 19 patients with a deficiency of glucose-6-phosphatase and 1 patient with a deficiency of glucose-6-phosphate translocase, the effect of nocturnal gastric drip feeding (GDF) on growth and plasma lipids and apolipoproteins was studied. The effect on growth was estimated by determining the height standard deviation score (SDS) of the patients and comparing its changes (ASDS) over 4-, 2-, and 1-y periods before and I-, 2-, 5-, and 8-y periods after the institution of GDF. The effect of G D F on plasma lipids and apolipoproteins was investigated by following the concentrations of triglycerides, cholesterol, and apolipoproteins A-I, A-11, B, C-I, C-11, C-111, and E. Growth caught up significantly or remained in the normal range in 14 patients. They were defined as responders to GDF. In the other six patients, growth caught up insufficiently or showed a further deceleration. They were defined a s nonresponders to GDF. G D F had only a temporary and marginal effect on plasma lipids and apolipoproteins, but after 5-8 y, the levels of plasma triglycerides, cholesterol, apolipoprotein, B, C-I, C-11, C-111, and E increased further in both responders and nonresponders, whereas apolipoproteins A-I and A-I1 decreased in nonresponders. There were minor differences in the levels of lipids and apolipoproteins between responders and nonresponders without any discernible trends during the first years of GDF. After 5-8 y, the levels of cholesterol, triglycerides and apolipoproteins B, C-I, C-11, C-111, and E seemed to be higher, and apolipoproteins A-I and A-I1 lower, in nonresponders than in responders, but the differences were not significant. (Pediatr Res 25:327-331, 1989) Abbreviations GSD-IA, glycogen storage disease caused by deficiency of glucose-6-phosphatase GSD-IB, glycogen storage disease caused by deficiency of glucose-6-phosphate translocase GDF, gastric drip feeding height SDS, height standard deviation score 
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The administration o f nocturnal GDF to patients with GSD-IA or GSD-IB has markedly improved their growth ( 1 , 2 GDF were collected from the referring pediatricians and from our own clinic. Our measurements of height were performed on a Harpendcn stadiometer. All heights were expressed as SDS, according to Tanner et a/. (7) . The SDS is defined as the patient's height minus the mean for the actual age, divided by the SD at that age. For this purpose, the 1980 nation-wide Dutch references (8) were used. In addition, the SDS corrected for parental height was calculated by subtracting the mean parental SDS from the child's SDS value. The parental SDS was calculated using the mean and S D of adult men's and women's heights in the 1965 nation-wide Dutch references (9) . Normally, the height SDS of a child remains stable after the age of approximately 4 y, which signifies that heights tend to keep their track on the percentile charts. Deviation from the normal track, i.e. a change in height SDS, is the growth parameter of interest when the effect of a disease or of a possibly growth-promoting treatment is investigated. We therefore calculated the change of height SDS over periods of 1, 2, and 4 y before and 1, 2, 5, and 8 y during G D F treatment. These values were all estimated by interpolation of the available height measurements. The values obtained over 1, 2, 4, and 5-y periods were compared with the 95% confidence intervals in a Finnish healthy child population (10) . Wt-forheight was expressed as a percentage of the median wt-for-height from the recent Dutch growth study (8) .
Laboratory methods. Venipuncture was performed for routine assay of electrolytes, urate, and liver and kidney function. Additional blood was taken for the lipoprotein studies with the consent of the parents and/or the patients. The venipuncture was performed in the nonfasting state because of the risk of fasting hypoglycemia. The preceding breakfast consisted of 1-2 slices of bread with margarine, jam, or marmalade, and tea with low-fat milk. EDTA blood samples were centrifuged at low speed, and the plasma was used for the determination of triglycerides and cholesterol by routine procedures (1 1, 12) . The remaining plasma was shipped immediately by airmail at ambient temperature from Groningen to Oklahoma City, OK, for apolipoproteins analyses. Plasma apolipoproteins were measured by electroin~munoassays as described earlier (6) .
Statistical methods. As a result of skewed distributions of lipid and apolipoprotein values in some patients, the significance of differences was estimated by the Wilcoxon rank sum test. The level of significance was taken a s p 5 0.05.
RESULTS

Growth analysis.
The height SDS at the start of G D F and its changes before and after the institution of G D F are shown in Table 1 . Before treatment, a negative growth deviation is seen in almost all children, and in many cases the height SDS is below the 2.5 percentile. After the institution of GDF, catch-up growth, indicated by positive SDS changes, is seen in most children. The SDS changes are above the p = 95 value in many cases. When the data are analyzed on a n individual basis, several patterns emerge. The most common pattern is growth retardation before the onset of treatment, followed by catch-up growth for a few years, and subsequently stable growth parallel to the percentile curves. This pattern is seen in cases 1-9, except that case 2 already showed accelerated growth before the start of GDF, probably because of more frequent feeding. These cases showed a normal distribution of height SDS (corrected for parental height SDS) from -1.14 to +2.86 after 5 y of GDF. Two patients, cases 10 and 11, had a normal growth before GDF, which did not substantially change subsequently, Cases 1-1 1 all have a growth pattern that can be considered as a satisfactory response to GDF. Two patients, cases 12 and 13, with significant catch-up growth can be expected to attain ultimately normal height SDS, although their height SDS at 5 y still were subnormal. Case 14 showed catch-up growth after the start of GDF, but the period of observation was not long enough to be certain that this catch-up growth will be adequate. Cases 15 and 16 had an early growth acceleration, followed by a lag. After 5 y of G D F they, and case 17, still showed a low height SDS (corrected for parental height SDS). This may be considered a n insufficient response.
Finally, three cases, 18-20, had a continued deceleration of growth, resulting in lower height SDS values during G D F than proteins of both responders and nonresponders were significantly different from those of normolipidemic, asymptomatic children (6) .
DISCUSSION
Improvement of growth in GSD-I patients, due to treatment with nocturnal GDF in conjunction with frequent feedings during the day, has been reported by many authors (1-3, 13) . The favorable effects of GDF have been attributed to the constant provision of fuel to peripheral tissues (14) . This is associated with a decrease of plasma glucagon and an increase of plasma insulin and growth hormone (1, 13) . These hormonal changes as well as an amelioration of the tendency toward lactic acidosis (3) and a normalization of the sleep pattern (2) may be factors contributing to the improvement of growth.
We used two criteria to substantiate a favorable response of the patients' growth to long-term GDF treatment. First, a significant upward deviation of height SDS from the track of growth before the institution of GDF. The calculation of significance was obtained by comparing the ASDS over 1-, 2-, and 5-y periods with the 95% confidence intervals of ASDS of a healthy Finnish child population (10) . This is applicable to growth-retarded patients showing catch-up growth, but not to patients who maintained a normal track before and during GDF. We defined the latter patients also as responders to GDF as long as their SDS remained above -2 and ASDS did not show a significant downward deviation. Using these two criteria, we consider our patients 1-1 1 to be definite responders, and cases 12-14 as probable responders.
Unlike these 14 responders, the other six patients reacted less favorably to GDF. Two patients (cases 15 and 16) showed only a temporary catch-up growth followed by deceleration. Three patients (cases 18-20) had a clearly downward deviation of height SDS.
Such a division of patients into responders and nonresponders might suggest the existence of two distinct groups of patients. However, this is obviously not the case because a transition zone exists between patients who respond conspicuously favorably to GDF and those who did improve with respect to vitality, appetite, excessive sweating, and sleep pattern but not with respect to growth. Yet, having defined some patients as nonresponders, we increased our efforts to search for dietary imperfections, endocrinologic abnormalities, and environmental interferences, but we failed to find any explanation for their insufficient growth during GDF. Thus, the decelerated growth could not be due to advanced glomerular sclerosis (15) , because of 14 patients in whom glomerular filtration rate and renal plasma flow were determined, increased values were found in nine and 12 patients, respectively; none of the patients showed decreased values. Tubular function, as estimated by the urinary excretion of PZ microglobulin and lysozyme, was normal. The abnormalities of renal function were not related to the growth rate of the patient, to the age at which GDF had been instituted, or to the age of the patient when tested.
With respect to the abnormalities of plasma lipids and apolipoproteins, which closely resembled those of Levy et al. (16) , no statistically significant differences existed between responders and nonresponders before the initiation of GDF treatment. GDF had a marginal effect on plasma lipids and apolipoprotein profiles after 1-2 y, but only in those patients whose growth responded favorably. These effects wore off after continued treatment, and ultimately plasma triglycerides, cholesterol, apolipoproteins B, C-111, and E increased to higher concentrations, and, conversely, apolipoproteins A-I and A-I1 decreased to lower concentrations than those characteristic of the pretreatment period, particularly in nonresponders. Therefore, neither the pre-GDF profile of plasma lipids and apolipoproteins, nor the post-GDF changes of the profile allowed one to predict if a patient's growth would respond favorably to GDF treatment, whereas a good correlation appears to exist between growth and such other metabolic abnormalities as 2-oxoglutarate and lactate (4) . The atherogenic character of the apolipoprotein profile (17) was not reflected in clinical symptoms of premature atherosclerosis in our patients. In four patients, aged 10, 14, 15, and 16 y, ultrasound study of the heart and ECG during excercise did not reveal abnormalities.
Probably the increased tendency to atherosclerosis that might be expected from the apolipoprotein profile is offset by the decreased adhesiveness of the platelets, characteristic of GSD I (18) . This would tally with the resistence to atherosclerosis in pigs with Von Willebrand's disease (1 9) and with the antiatherogenic effect of such platelet-inhibiting drugs as aspirin in the human.
The absence of atherosclerotic symptoms in our patients does not mean that the abnormalities of plasma lipids and apolipoproteins do not have pathologic implications. Although no etiologic mechanism is known, the elevated lipid and apolipoprotein levels may be involved in the development of glomerular disease (20) , the initial phase of which was found in 10 of our 20 patients. We have previously suggested (6) that the molar ratio of apolipoproteins B/C-III/E of 1:4-5:l might reflect mainly the overproduction of some triglyceride-rich lipoprotein particles (21) . The increased liponeogenesis may be the consequence of an enhanced glycogenolytic flux through an enlarged glucose-6-phosphate pool (22) , resulting not only in increased pyruvate and lactate formation (4) but in increased production of malonylCoA as well. The latter is the main substrate of fatty acid synthesis from pyruvate (23) . Thus, lactate overproduction, which has been shown to be very sensitive to insufficient glucose availability (4), may be the first outlet of excessive glycogenolysis; endogenous triglyceride overproduction reflected in hyperlipoproteinemia would be a relatively insensitive and quantitatively larger second outlet (3) . This abnormality appears to be less easily corrected by GDF than growth, the latter being usually, though not always, responsive to dietary manipulation.
